Navigation Links
AstraZeneca and M. D. Anderson Renew Cancer Research Collaboration
Date:10/29/2008

Alliance extended for a further five years

WILMINGTON, Del. and HOUSTON, Oct. 29 /PRNewswire/ -- AstraZeneca and The University of Texas M. D. Anderson Cancer Center today announced they have renewed their collaboration to integrate pre-clinical and clinical research with a view to speeding up access to new medicines of potential benefit to cancer patients.

The collaboration facilitates interactions between physicians and scientists in both organizations to combine resources and expertise in disease intervention whilst providing flexibility to work in a variety of ways and accelerate the development of new treatments. It is unusual in its focus on pre-clinical research and the transition to clinical trials and was the first of its kind for both institutions.

Since its launch in 2005, the collaboration has utilized AstraZeneca's early development portfolio to generate over two dozen joint research projects. Both parties intend to build on these by extending the collaboration for a further five years and broadening its original focus from aerodigestive diseases (head and neck cancers and lung cancer) to include targets with potential in a variety of cancer settings.(1)

Brent Vose, Vice President of AstraZeneca's Oncology Therapy Area said: "AstraZeneca is committed to the research and development of new, targeted anti-cancer therapies to improve the lives of cancer patients.

"We have a number of promising compounds in development and look forward to seeing the results of some key studies throughout the next year.

"Our collaboration with M.D. Anderson has proven our ability to speed up the drug development process without compromising quality and we look forward to building on our joint efforts to date."

Close cooperation in areas of common interest is essential to meet the challenge of safe, accelerated drug development according to Robert C. Bast Jr., M.D., Vice President for Translational Research at M. D. Anderson who said: "Earlier access to drugs destined for the clinic has permitted the identification of biomarkers and combinations with existing agents that will permit individualization of cancer treatment.

"In an atmosphere of trust and collaboration, it has been possible to eliminate unnecessary delays in moving drugs into the clinic. In one case, we reduced the time to initiate a Phase I clinical trial by 3 months, while fully meeting regulatory requirements.(2)

"For patients with cancer, delays are unacceptable. We look forward to continuing our relationship with AstraZeneca to make even more rapid progress in evaluating drugs that are likely to benefit our patients."

AstraZeneca's collaboration with M.D. Anderson Cancer Center has formed the benchmark for a number of subsequent collaborations with institutions in the USA, Europe and Asia. Similarly, M. D. Anderson has since entered into alliance relationships with other pharmaceutical and biotech companies and modelled those after the AstraZeneca agreement.

While the specific terms of the renewed collaboration remain confidential, it covers the sharing of intellectual property, M. D. Anderson's rights to publish research results and funding commitments by AstraZeneca.

About AstraZeneca

AstraZeneca is a major international healthcare business engaged in the research, development, manufacturing and marketing of meaningful prescription medicines and supplier for healthcare services. AstraZeneca is one of the world's leading pharmaceutical companies with healthcare sales of $29.55 billion and is a leader in gastrointestinal, cardiovascular, neuroscience, respiratory, oncology and infectious disease medicines. In the United States, AstraZeneca is a $13.35 billion dollar healthcare business with 12,200 employees committed to improving people's lives. AstraZeneca is listed in the Dow Jones Sustainability Index (Global) as well as the FTSE4Good Index.

For more information visit http://www.astrazeneca-us.com.

About M.D. Anderson

The University of Texas M.D. Anderson Cancer Center in Houston ranks as one of the world's most respected centers focused on cancer patient care, research, education and prevention. M.D. Anderson is one of only 41 Comprehensive Cancer Centers designated by the National Cancer Institute. For six of the past nine years, M.D. Anderson has ranked No. 1 in cancer care in "America's Best Hospitals", a survey published annually in U.S. News and World Report.


'/>"/>
SOURCE AstraZeneca
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. FDA Approves AstraZenecas SEROQUEL XR(R) for the Treatment of Bipolar Depression and Bipolar Mania
2. Melior Enters Research Collaboration with AstraZeneca
3. Abbott and AstraZeneca Expand Relationship to Include Co-Promotion of CRESTOR(R)
4. AstraZeneca Survey: Healthcare Professionals Leading Source of Information on Companys Prescription Savings Programs
5. Weitz & Luxenberg Files Seroquel Diabetes Lawsuit Against AstraZeneca
6. Cellectricon and AstraZeneca - Partners in New High Throughput Ion Channel Drug Discovery Technology
7. WuXi PharmaTech (NYSE: WX) Expands Collaboration With AstraZeneca
8. AstraZeneca Supports Transparency Legislation on Payments to Health Care Providers
9. Ranbaxy and AstraZeneca Reach Agreement in Esomeprazole Patent Litigation
10. AstraZenecas Zactima to Earn Almost Five Percent Patient Share in the Treatment of Non-Small-Cell Lung Cancer by 2016
11. Silence Therapeutics and AstraZeneca Announce Collaboration to Develop Novel Approaches for siRNA Drug Delivery
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2017)... ... June 27, 2017 , ... Indiana-based Xylogenics announced today ... and fermentation process. The efficiencies created by the newest strain design will ... the ethanol industry wherein individual production plants are planning to invest upwards of ...
(Date:6/26/2017)... ... June 26, 2017 , ... ... the former Associate Director of Product Development R&D at Allergan and CMC expert ... at both start-up and established biopharma companies, has joined the firm as an ...
(Date:6/26/2017)... ... June 26, 2017 , ... The Workgroup for ... health IT to create efficiencies in healthcare information exchange and a statutory advisor to ... MD, head of the federal Office of the National Coordinator for Health Information Technology, ...
(Date:6/23/2017)... , ... June 23, 2017 , ... Biova, LLC., the ... has joined Biova’s Board of Directors. Dr. Henig will bring a wealth of scientific ... has served as the Chief Technical and Scientific Officer of four major global companies ...
Breaking Biology Technology:
(Date:4/5/2017)... Allen Institute for Cell Science today announces the launch ... dynamic digital window into the human cell. The website ... deep learning to create predictive models of cell organization, ... suite of powerful tools. The Allen Cell Explorer will ... resources created and shared by the Allen Institute for ...
(Date:4/4/2017)... April 4, 2017   EyeLock LLC , a ... the United States Patent and Trademark Office (USPTO) has ... the linking of an iris image with a face ... represents the company,s 45 th issued patent. ... very timely given the multi-modal biometric capabilities that have ...
(Date:3/30/2017)... , March 30, 2017 The research ... system for three-dimensional (3D) fingerprint identification by adopting ground breaking 3D ... a new realm of speed and accuracy for use in identification, ... an affordable cost. ... ...
Breaking Biology News(10 mins):